Abstract Number: 1522 • ACR Convergence 2020
Biomarkers of Hemodynamic Severity of Systemic-Sclerosis Associated Pulmonary Arterial Hypertension by Serum Proteome Analysis
Background/Purpose: To investigate alterations in the serum proteome of patients with systemic sclerosis (SSc)-associated pulmonary hypertension (PAH), to identify proteins that correlated with hemodynamic severity…Abstract Number: 0491 • ACR Convergence 2020
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…Abstract Number: 1694 • ACR Convergence 2020
Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America
Background/Purpose: Pneumocystis jirovecii pneumonia (PJP) is associated with significant morbidity and mortality in adult myositis patients; however, few studies have examined PJP in juvenile myositis…Abstract Number: 0520 • ACR Convergence 2020
Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward
Background/Purpose: A high prevalence of thrombotic events has been reported in critically ill COVID-19 patients but data on the prevalence of thrombosis in ward patients…Abstract Number: 1695 • ACR Convergence 2020
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
Background/Purpose: A subset of juvenile dermatomyositis (JDM), clinically amyopathic dermatomyositis (CADM), is uncommon and mainly described in adults. CADM is classically characterized by skin ulcerations,…Abstract Number: 0785 • ACR Convergence 2020
Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for comorbid chronic lung disease, with premature mortality. Therapies for RA-associated lung disease are…Abstract Number: 1908 • ACR Convergence 2020
Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis
Background/Purpose: Pulmonary arterial hypertension (PAH) occurs either primarily or in association with other diseases such as connective tissue diseases. PAH associated with systemic sclerosis (SSc-PAH)…Abstract Number: 0912 • ACR Convergence 2020
Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension
Background/Purpose: Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) has been known as a life-threatening manifestation in SSc. Earlier detection and subsequent interventions are important to improve…Abstract Number: 1957 • ACR Convergence 2020
A Single Cell Stromal Atlas Identifies Conserved Fibroblast Phenotypes Expanded in the Inflamed Synovium, Lung, Intestine, and Salivary Gland
Background/Purpose: Pro-inflammatory fibroblasts have been independently implicated in the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), interstitial lung disease (ILD), and Sjogren’s syndrome…Abstract Number: 0925 • ACR Convergence 2020
Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension
Background/Purpose: Systemic sclerosis (SSc) patients are at high risk for pulmonary hypertension (PH), a leading cause of death in this population. Chloroquine is a pulmonary…Abstract Number: 1038 • ACR Convergence 2020
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis
Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…Abstract Number: 1039 • ACR Convergence 2020
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…Abstract Number: 1040 • ACR Convergence 2020
Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand
Background/Purpose: Data on clinical manifestations of Asians with sarcoidosis are still relatively limited and most of the previously published studies are from East Asia. This…Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…
ACR Meeting Abstracts